WARD Glucose Validation

WARD Glucose Validation

Study design
Prospective study/cohort
Sample size
60 participants
Principal Investigator

Casper Pedersen, MD PhD student

Study sites

Rigshospitalet and Bispebjerg Hospital

Inclusion criteria

Adult patients with diabetes mellitus who a) undergo surgery lasting >45 minutes or b) are admitted to the intensive care unit (ICU) with circulatory impairment (requiring continuous infusion of vasopressors and a reduced peripheral perfusion).

Study procedures

Included patients will wear a continuous glucose monitoring (CGM) device (Dexcom G7) during the stay at the hospital (up to 10 days). Through a sensor placed subcutaneously, the Dexcom G7 measures glucose levels every 5 minutes and transmit readings this to a receiver at the patient bed. The glucose readings will be blinded to the patients and nursing staff. Thus, the patients’ glucose levels will be monitored through standard practice with point-of-care (POC) blood glucose measurements. After the study period, the accuracy of CGM readings will be assessed by comparing these to POC blood glucose measurements.

Outcome

The primary outcome is the accuracy of the CGM device compared to standard POC blood glucose measurements.

Trial registration
NCT06297850